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Royal Devon and Exeter National Health Service Foundation Trust, Exeter, UKHeterozygous mutations of the HNF1B gene are the
commonest known monogenic cause of developmental
kidney disease. Half of patients have a deletion
(approximately 1.3 Mb) of chromosome 17q12,
encompassing HNF1B plus 14 additional genes. This 17q12
deletion has been linked with an increased risk of
neurodevelopmental disorders, such as autism. Here we
compared the neurodevelopmental phenotype of 38
patients with HNF1B-associated renal disease due to an
intragenic mutation in 18 patients or due to 17q12 deletion
in 20 patients to determine whether haploinsufﬁciency
of HNF1B is responsible for the neurodevelopmental
phenotype. Signiﬁcantly, brief behavioral screening in
children with the deletion showed high levels of
psychopathology and its impact. Eight individuals (40%)
with a deletion had a clinical diagnosis of a
neurodevelopmental disorder compared to none with an
intragenic mutation. The 17q12 deletions were also
associated with more autistic traits. Two independent
clinical geneticists were able to predict the presence of a
deletion with a sensitivity of 83% and speciﬁcity of 79%
when assessing facial dysmorphic features as a whole.
Thus, the 17q12 deletions but not HNF1B intragenic
mutations are associated with neurodevelopmental
disorders. Hence, the HNF1B gene is not involved in the
neurodevelopmental phenotype of these patients.
Nephrologists need to be aware of this association to
ensure appropriate referral to psychiatric services.
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H eterozygous mutations in the gene encoding thetranscription factor hepatocyte nuclear factor 1b(HNF1B) are the commonest known monogenic
cause of developmental kidney disease.1–3 The phenotype of
HNF1B-associated renal disease is very variable despite this
single genetic etiology. Abnormalities are often detected on
prenatal ultrasonography, where bilateral hyperechogenic kid-
neys with normal or slightly increased size are commonly
found.4 Cystic disease, including cystic dysplasia, is usually
seen in both pediatric and adult populations but other devel-
opmental kidney disease has been reported, including single
kidneys, hypoplasia, horseshoe kidneys, duplex kidneys,
collecting system abnormalities, bilateral hydronephrosis
and hyperuricemic nephropathy.1,5–11 Electrolyte abnormal-
ities, including hypomagnesemia and hyperuricemia, are
common.10,11 HNF1B-associated disease is a multisystem
disorder; extrarenal phenotypic features include early onset
diabetes mellitus, pancreatic hypoplasia, genital tract malfor-
mations, and abnormal liver function tests.12–17 Genetic
changes in the HNF1B gene comprise either whole-gene dele-
tions (approximately one-half of patients) or intragenic mu-
tations (base substitutions or small insertions/deletions
within the HNF1B gene).8,18 Both may arise spontaneously;
50% of whole-gene deletions are de novo.4,7,19 This means
there is frequently no family history of renal disease or
diabetes.
The majority of patients with a whole-gene deletion
have an approximate 1.3 Mb deletion at chromosome
17q12, which includes the entire HNF1B gene.20 These
recurrent microdeletions of 17q12 are mediated by203
Table 1 | Characteristics of study patients with either an HNF1B intragenic mutation or 17q12 microdeletion
HNF1B mutation
(n [ 18)
17q12 microdeletion
(n [ 20) P
Age, yr 19 (13, 45) 15.5 (11, 35) 0.3
Sex M 8 (44%), F 10 (56%) M 8 (40%), F 12 (60%) 1
Ethnicity White 18 (100%) White 19 (95%), mixed 1 (5%) 1
Indices of Deprivation 2007 score 25 (16, 46) 21 (12, 30) 0.4
Renal phenotype
Renal abnormality
Cysts/cystic dysplasia 12 (67%) 17 (85%) 0.3
Othera 4 (22%) 3 (15%)
Unknown 2 (11%) 0
Age at diagnosis of renal disease, yr 0 (0, 20) 0 (0, 24) 0.7
Renal replacement therapy 3 (17%) 1 (5%) 0.3
GFR, ml/min/1.73 m2 42.6 (31, 60) 81.4 (56, 91) 0.002
Proteinuriab,c 2 (13%) 2 (11%) 1
Serum magnesium,c mmol/l 0.7 (0.67, 0.75) 0.58 (0.53, 0.69) 0.01
Hypomagnesemiac,d 6 (40%) 12 (63%) 0.3
Hyperuricemiac,e 10 (67%) 3 (16%) 0.004
Gout 6 (33%) 2 (10%) 0.1
Extra-renal phenotype
Pancreas
Diabetes 7 (39%) 8 (40%) 1
Age at diagnosis of diabetes 19 (18, 37) 29 (17, 32) 1
Pancreatic hypoplasiaf,g 1 (6%) 5 (25%) 0.2
Fecal elastase, mg/g stool 402.5 (170, 500) 280 (167, 433) 0.8
Genital tract
Genital tract malformationg,h 1 (6%) 2 (10%) 1
Liver
Abnormal liver function testsg 5 (28%) 6 (30%) 1
Values are median (IQR) or n (%). Bold P-values are statistically signiﬁcant.
F, female; GFR, glomerular ﬁltration rate; IQR, interquartile range; M, male.
aOther renal structural abnormalities included single kidney, collecting system abnormalities, and bilateral hydronephrosis.
bProteinuria deﬁned as albumin-creatinine ratio >30 mg/mmol or protein-creatinine ratio >50 mg/mmol.
cOnly assessed in individuals with native renal function.
dHypomagnesemia deﬁned as serum magnesium <0.7 mmol/l.
eHyperuricemia deﬁned as serum urate level above upper limit of normal reference range for age and sex from analyzing laboratory.
fHypoplasia of body and/or tail of pancreas.
gNot systematically assessed for.
hGenital tract malformations included (i) unilateral undescended testicle and blind-ending epididymis, (ii) bilateral undescended testicles, and (iii) bicornuate
uterus.
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recombination.21 Unlike most genomic disorders, the
17q12 deletion was not initially thought to be associated
with developmental delay or intellectual disability. More
recent work has shown that neurodevelopmental disorders,
including autism spectrum disorders (ASD), are part of the
phenotype in patients referred for testing via clinical ge-
netics rather than renal services.22–26 A study by Laffargue
et al.20 suggests that the neuropsychological phenotype is
less severe than that previously reported when the 17q12
deletion is identiﬁed secondary to renal abnormalities.
Comparison of 26 children with HNF1B deletions and 13
with point mutations under the care of pediatric ne-
phrologists showed no signiﬁcant differences in relation to
learning abilities and schooling, although the deletion
group tended to have lower intelligence quotients (IQs)
and more educational difﬁculties at school than those with
a mutation. However, formal neuropsychological evalua-
tion was only carried out in a small subset of the cohort
(11 of 39) and several of the children included in the study204were too young to evaluate for schooling difﬁculties
and ASD.
The 1.3 Mb deleted region contains 14 genes in addition to
HNF1B and it is not clear what genetic mechanism gives rise
to this neurodevelopmental phenotype. One hypothesis is
haploinsufﬁciency of 1 of these 15 genes. HNF1B is involved
in hindbrain development in both zebra ﬁsh and mice and so
is a good candidate to be the etiological gene.27,28 There have
been rare reports of learning difﬁculties and epilepsy in 5
patients with HNF1B gene mutations, which would support
this.6,12,29 Another candidate is LHX1, which is also expressed
in the brain during early development; a mouse model with a
targeted mutation of Lhx1 conﬁrms its role as a key regulator
of the vertebrate head organizer.30,31 A study investigating
new hotspots of copy-number variation associated with ASD
has implicated ACACA within the 17q12 deletion.32 However,
no single gene deletions or mutations resulting in hap-
loinsufﬁciency and neurological disease in humans have been
detected in either of these genes to date. An alternative hy-
pothesis would involve more complex interactions betweenKidney International (2016) 90, 203–211
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Figure 1 | Patient difﬁculties as shown by parent-reported Strengths and Difﬁculties Questionnaire (SDQ) scores (presented as
Z-scores) for individuals <18 years with both HNF1B gene mutations (n [ 4) and 17q12 microdeletions (n [ 10). Individual scores
are represented as different-shaped points and group medians as black bold horizontal lines. The X-axis represents school-age population
mean, and the red dashed horizontal line above represents the suggested clinical cut-point (90th percentile).
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factors giving rise to an increased risk of neurodevelopmental
disorders.20 In this study, we systematically compared the
neurodevelopmental phenotype of patients with either an
HNF1B intragenic mutation or 17q12 deletion to determine
whether haploinsufﬁciency of the HNF1B gene is responsible
for this aspect of the phenotype.
RESULTS
General characteristics are similar in both HNF1B mutation
and deletion groups
Thirty-eight individuals participated in the study; 18 (47%)
had a known intragenic HNF1B mutation and 20 (53%) had
a whole-gene deletion. The intragenic mutations included
4 nonsense, 13 insertions/deletions, and 1 missense change
(Supplementary Table S1). The presence of the common
1.3 Mb 17q12 deletion was conﬁrmed by dosage analysisa
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Kidney International (2016) 90, 203–211of ZNHIT3 and HNF1B, the most 50 and 30 of the 15 genes
within the interval, by droplet digital polymerase chain re-
action (PCR) in the deletion group (data not shown).
Both mutation and deletion groups were similar in terms
of general characteristics (Table 1). Median age at study
inclusion was similar between the groups, as was sex break-
down. Participants were predominantly of White British
origin, reﬂecting the fact that 61% were recruited from South
West England. Levels of deprivation were similar in both
mutation and deletion groups as measured using the median
Index of Multiple Deprivation 2007 score. Cysts or cystic
dysplasia were the renal phenotype seen most commonly
in both groups, similar to cohorts with HNF1B-associated
kidney disease previously described in the literature.5 Renal
function was worse in the mutation group with a median
estimated glomerular ﬁltration rate (GFR) of 42.6 ml/min/
1.73 m2 (interquartile range [IQR]: 31, 60) compared withb
lopmental
gnosis of
lopmental
ked bar chart showing percentage of patients within both 17q12
wn neurodevelopmental disorder including autism spectrum disorder
ifﬁculties requiring a Statement of Special Educational Needs or
own and overlap of diagnoses in the 8 patients with a deletion and
205
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magnesium levels were lower in the deletion group, whereas
hyperuricemia was more common in the mutation group;
both of these ﬁndings may be explained by the greater degree
of renal impairment seen in the mutation group. Diabetes
was present in approximately 40% of patients in both groups.
Other extrarenal phenotypes were also similar between mu-
tation and deletion groups.
The 38 patients included in this study represented 45% of
those with HNF1B-associated disease who were eligible to
take part from the 4 different sites. Supplementary Table S2
compares the general characteristics of participants and
nonparticipants. Brieﬂy, the 2 groups were similar in terms of
genetic abnormality, age, sex, levels of deprivation, and renal
phenotype. The only difference was in ethnicity, with other
ethnic groups besides White British being more commonly
represented among nonparticipants. However, the data
available for nonparticipants was incomplete with 13 of 47
(28%) having no information on ethnicity recorded.
Brief behavioral screening shows higher levels of psychopa-
thology and impact in children with a deletion
Use of the parent-reported Strengths and Difﬁculties Ques-
tionnaire (SDQ) revealed more patient difﬁculties in the dele-
tion group with a median total difﬁculties score of 15.5 (IQR:
10, 20) compared with 7 in the mutation group (IQR: 3.5, 7.5;
P ¼ 0.048) (Figure 1). This is also higher than the mean total
difﬁculties score of 8 5.8 (SD) obtained in a normative sample
of 10,438 British school-aged children.33 When analyzing the 4
subsections of the total difﬁculties score, conduct problems and
peer relationship problems were more common in the deletion
group as follows: median scores were 2.5 (IQR: 2, 5) and 4.5
(IQR: 1, 6), respectively, versus 0.5 (IQR: 0, 1) and 0 (IQR: 0,
0.5) in the mutation group, P ¼ 0.04 and 0.02, respectively
(Supplementary Figure S1). Five of the 10 children with a
deletion scored above the suggested clinical cut-point of 15; all
of these children apart from 1 had already been referred for
further psychological evaluation.
Parental scores for the impact of these difﬁculties on the
child’s life were similarly high in the deletion group with aa
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Figure 3 | Quantiﬁcation of autistic traits using the Autism Spectrum
normal intelligence (deﬁned as Intelligence quotient [IQ] > 69). (a)
patients with a clinical diagnosis of an autism spectrum disorder ([ASD]
206median score of 5 (IQR: 2, 8). This was compared with a
median score of 0 in the mutation group (IQR: 0, 0; P ¼ 0.02)
and a mean score of 0.4  1.1 in the large normative sample
mentioned previously.33
Clinical diagnosis of neurodevelopmental disease in patients
with a deletion
Eight of 20 participants (40%) with a deletion had a clinical
diagnosis of either an ASD, attention deﬁcit hyperactivity
disorder (ADHD), and/or learning difﬁculties requiring a
Statement of Special Educational Needs or current attendance
at a special school compared with 0 of 18 with a mutation,
P ¼ 0.004 (Figure 2a). Of these 8 patients, 4 had comorbidity
with learning difﬁculties accompanying a diagnosis of ASD
and/or ADHD (Figure 2b, Supplementary Table S3). Ac-
cording to the second national survey of children’s mental
health and well-being carried out in 2004, the prevalence of
ASD in British children was 0.9% and hyperkinetic disorder/
ADHD was 1.5%.34 Therefore, the frequency of ASD and
ADHD found in participants with a deletion in this study far
exceeds the baseline population rates.
17q12 deletions are associated with more autistic traits
Patients with a deletion had a higher median Autism Spec-
trum Quotient (AQ) (43% [IQR: 28, 68] vs. 29% [IQR: 16,
42] in the mutation group, P ¼ 0.02), indicating a greater
number of autistic traits (Figure 3a). Although the AQ is not a
diagnostic tool, cutoffs have been described for identifying
individuals who may have clinically signiﬁcant levels of
autistic traits. However, referral for a full diagnostic assess-
ment is only warranted if the individual is also suffering
a degree of distress as a result of these traits.35–37 Six of
38 participants (16%) scored above the suggested cutoff; of
these, all had a deletion and 3 of 6 had a conﬁrmed diagnosis
of ASD. To see whether the AQ results were being skewed by
a small number of individuals with a high number of autistic
traits, the analysis was repeated after excluding those with a
known ASD. Although there was a trend toward a higher AQ
in the deletion group (median AQ: 36% [IQR: 28, 52] vs. 29%
[IQR: 16, 42] in the mutation group), this did not reachb
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done so in a larger sample (n ¼ 64).
Cognitive ability is similar in both HNF1B mutation and
deletion groups
The median IQ composite was similar in both mutation
and deletion groups (97 [IQR: 83, 104] vs. 91 [IQR: 76, 107];
P ¼ 0.6) (Figure 4). Two participants with a deletion scored in
the lower extreme category with IQ < 70.
Facial dysmorphic features considered as a whole may be
predictive of the presence of a 17q12 deletion
Facial photographs were analyzed in 33 participants (18
with an intragenic HNF1B mutation, 15 with a deletion).
None of the facial dysmorphic features previously described
in association with the 17q12 deletion differed in frequency
between the mutation and deletion groups (Supplementary
Table S4). Variation in results between the 2 assessors was
seen although overall interrater agreement was fair with a
kappa coefﬁcient of 0.4 (95% conﬁdence interval: 0.3–0.5).
When facial dysmorphic features were considered as a
whole by both assessors to predict whether an individual
had a deletion, sensitivity was 83% and speciﬁcity was 79%
(Figure 5). Nine of 37 patients (24%) had a head circum-
ference >90th percentile, but there was no difference in
macrocephaly between the 2 groups (5 of 19 [26%] in
deletion group vs. 4 of 18 [22%] in mutation group,
P ¼ 1).
DISCUSSION
The results of this study demonstrate that a neuro-
developmental phenotype is only seen in individuals with a
17q12 deletion. Compared with patients with an intragenic
mutation, patients with a deletion had a greater number of
autistic traits using the AQ and children displayed higher
levels of psychopathology and impact on brief behavioral
screening using the parent-reported SDQ. Indeed, 40% of
participants with a deletion had been clinically diagnosed
with a neurodevelopmental disorder; ASD and ADHD were
seen much more commonly in the deletion group than wereUpper extreme
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Figure 4 | Intelligence quotient (IQ) composite scores in
individuals with HNF1B-associated disease. Different IQ
classiﬁcations are shown by the red dashed horizontal lines.
Kidney International (2016) 90, 203–211predicted from population prevalence rates. Most (17 of 18)
of the patients with intragenic mutations had a nonsense or
insertion/deletion loss of function mutation, predicted to
result in reduced protein expression. The discrepancy in
neurodevelopmental phenotype between the intragenic mu-
tation and deletion groups suggests it is not simply hap-
loinsufﬁciency of the HNF1B gene that is responsible for this
aspect of the phenotype in individuals with a 17q12 deletion.
Our ﬁndings highlight the importance for nephrologists
to be aware of this association between 17q12 microdeletion
and neurodevelopmental disease to ensure referral to psy-
chiatric services where appropriate. The features of condi-
tions such as ASD can range from mild to severe and can
also ﬂuctuate over time and in response to different life
events; this variable expression adds to the diagnostic
challenges posed by these disorders.38 Individuals with a
deletion and their families should be informed of the
increased risk of a neurodevelopmental disorder so they can
report any concerning symptoms if they arise to allow
prompt investigation.
The results of this study contrast with recent work
concluding that when children are diagnosed with a 17q12
deletion secondary to renal abnormalities, the neuro-
developmental phenotype is less severe than previously sug-
gested in the literature.20 In this French cohort, only 1 of 26
patients with an HNF1B whole-gene deletion were diagnosed
with autism as compared to 0 of 13 in the mutation group.
However, the percentage of children with normal school
progression requiring no educational support was lower in
the deletion group (62.5% vs. 82%). It is possible that the lack
of statistical difference between the 2 groups in terms of
psychomotor development, school progression, and educa-
tional support may be explained by the younger age at study
inclusion. Although both studies included a similar number
of participants and all had HNF1B-associated disease identi-
ﬁed secondary to renal disease or diabetes, the median age at
inclusion was only 5.5 years (range 0.8–17) compared with 17
years (range 4–65) in our UK cohort. Schooling difﬁculties
cannot be assessed in the very young and the features of
neurodevelopmental disease may be more apparent as chil-
dren become older; the median age at diagnosis of ASD,
ADHD, and learning difﬁculties in our cohort was 8 years
(IQR: 5.5, 9.5). Earlier work from another French cohort of
53 children with hyperechogenic or cystic kidneys and a
17q12 deletion reported autism in 3 cases (5.7%), a greater
proportion than predicted from the prevalence of ASD in the
pediatric population.39 This is in keeping with the increased
frequency of ASD in deletion patients we described in our
study.
When considered in isolation, none of the facial dysmor-
phic features previously described in association with a 17q12
deletion was statistically more common in the deletion group
in this study. This contrasts with ﬁndings by Laffargue et al.,20
who reported that a high forehead, deep set eyes, and
chubby cheeks were more frequently seen in the presence of
a deletion rather than a mutation.20 However, when the207
Figure 5 | Photographs of 2 study patients with a known HNF1B whole-gene deletion demonstrating the high forehead, high arched
eyebrows, long philtrum, long face, and anteverted nares that, taken as a whole, suggest the presence of a deletion.
c l i n i ca l i nves t iga t i on RL Clissold et al.: Neurodevelopmental phenotype in HNF1B diseasecraniofacial characteristics in our series were assessed as a
whole, 2 independent clinical geneticists were able to predict
the presence of a deletion with a sensitivity of 83% and
speciﬁcity of 79%. This supports the prior hypothesis that
the 17q12 deletion is associated with a mild but character-
istic facial phenotype22 and that another genetic mechanism
besides HNF1B haploinsufﬁciency is causative.
Interestingly, we found that patients with an intragenic
HNF1B mutation had a signiﬁcantly lower median estimated
GFR than patients with a deletion, although this is unlikely to
be related to the neurodevelopmental differences between the
2 groups. Ulinski et al.7 described the phenotype of 25 chil-
dren with HNF1B-associated renal disease and found no
difference in renal function between individuals with an
HNF1B whole-gene deletion and those with point mutations.
A later series that included 75 patients with HNF1B-
associated renal disease showed that the proportion of in-
dividuals with renal impairment was signiﬁcantly higher
in those with a truncating mutation (nonsense, frameshift, or
splice site) than in those with a deletion (P ¼ 0.01).5 The
investigators hypothesized that the older age of the patients
with truncating mutations may partly explain the difference208in renal function between the 2 groups; however, the muta-
tion and deletion groups in our study were similarly matched
in terms of median age. Seventeen of 18 intragenic mutations
described in our series were truncating.
The results from this study provide the ﬁrst detailed
description of the neurodevelopmental phenotype of both
children and adults diagnosed with HNF1B-associated dis-
ease. Both mutation and deletion groups were similarly
matched in terms of general characteristics, and participants
were systematically assessed for neurodevelopmental features
using validated screening tools. However, several limitations
were associated with this work. Despite inviting all eligible
patients from the 4 different sites to take part, the study
cohort represented only 45% of the total due to either
inability to contact individuals despite several attempts or a
negative response to participation. Therefore, the exact
prevalence and spectrum of neurodevelopmental disorders
in HNF1B-associated renal disease and diabetes remains
unknown. Although individuals were systematically assessed
using a combination of screening tools, participant/parent
interview, and review of medical records, comprehensive
screening tools and diagnostic tests for ASD and ADHDKidney International (2016) 90, 203–211
RL Clissold et al.: Neurodevelopmental phenotype in HNF1B disease c l i n i ca l i nves t iga t ionwere not used. This means less severe disease may have
been missed. Finally, genetic screening for other known
causes of neurodevelopmental disease (e.g., Fragile X, other
copy number variants) was not undertaken.
None of the patients with an intragenic HNF1B mutation
in our study had a diagnosis of ASD, ADHD, or signiﬁcant
learning difﬁculties. Five individuals with HNF1B-
associated disease secondary to gene mutation and either
learning difﬁculties and/or epilepsy have been described,
although other genetic causes were not excluded.6,12,29 To
date, there have been no reports of HNF1B intragenic
mutation and either ASD or ADHD presented in the liter-
ature. This supports our hypothesis that it is not hap-
loinsufﬁciency of the HNF1B gene that is responsible for
this aspect of the phenotype in individuals with a 17q12
deletion. It also highlights that further work is needed in
this area to determine the cause of the phenotypic variability
seen in these patients.
In summary, 17q12 microdeletions but not intragenic
mutations are associated with a neurodevelopmental pheno-
type. All affected families should be informed of this risk
and referred for appropriate psychiatric assessment if con-
cerning symptoms arise.MATERIALS AND METHODS
Recruitment and HNF1B genetic analysis
Participants were recruited from January 31, 2013 to October 10,
2015 from 4 sites in the United Kingdom (adult renal and diabetes
units at the Royal Devon and Exeter Hospital; pediatric renal units at
Great Ormond Street Hospital for Children, Evelina London Chil-
dren’s Hospital, and Birmingham Children’s Hospital). Inclusion
criteria included the presence of either an HNF1B intragenic mu-
tation or whole-gene deletion on genetic testing performed due to
underlying renal abnormalities or diabetes and current age $4 years.
All eligible patients were invited to participate. Informed written
consent was obtained from all adult participants and parents of child
participants, with assent from those aged <16 years. The study was
conducted in agreement with the Declaration of Helsinki principles
and approved by a regional ethics committee (National Research
Ethics Service Committee South West—Frenchay). A total of 38
patients from 28 unrelated families with HNF1B-associated disease
agreed to participate.
Initial mutation screening was performed by sequencing of
coding exons and exon-intron boundaries together with gene
dosage assessment by multiplex ligation-dependent probe ampli-
ﬁcation as previously described.8,19 Droplet digital PCR was used to
conﬁrm the presence of an approximate 1.3 Mb deletion at chro-
mosome 17q12 in the 20 patients with an HNF1B whole-gene
deletion. This assay measured gene dosage for ZNHIT3 and
HNF1B, the most 50 and 30 genes within the recurrent 1.3 Mb
17q12 deletion. Droplet digital PCR was performed using the Bio-
Rad QX200 (Bio-Rad Laboratories, Hercules, CA) and following
standard protocols. Brieﬂy, a reaction mix containing 22 ng
genomic DNA, primers, and QX200 ddPCR EvaGreen supermix
(Bio-Rad Laboratories) was subjected to the automated QX200
Droplet Generator (Bio-Rad Laboratories) to produce emulsions
according to the manufacturer’s instructions. After PCR using a
standard thermocycler (Bio-Rad Laboratories), sample ﬂuorescenceKidney International (2016) 90, 203–211was assessed by the QX200 Droplet Reader (Bio-Rad Laboratories)
and absolute quantiﬁcation of ampliﬁed DNA product was deter-
mined by Poisson distribution using QuantaSoft software (Bio-Rad
Laboratories). A full methodology, including primer sequences, is
available on request.
Clinical evaluation
Renal and extra-renal involvement in participants, including
neurodevelopmental disorders, was documented using a stan-
dardized assessment of medical records and participant/parent
interview in all cases plus educational psychology reports where
available. An Index of Multiple Deprivation 2007 score was derived
for each participant using their postcode and was used as an
overall measure of deprivation. Imaging results from ultrasonog-
raphy, computed tomography, or magnetic resonance imaging
were reviewed to look for kidney, pancreas, and genital tract ab-
normalities. GFR was estimated using the (i) Schwartz-Haycock
formula in children,40 optimized for children with renal malfor-
mations assessed in each individual pediatric renal unit where
possible, and (ii) simpliﬁed Modiﬁcation of Diet in Renal
Disease formula in adults.41 GFR was set at 0 for patients on
renal replacement therapy. Proteinuria was deﬁned as albumin-
creatinine ratio >30 mg/mmol or protein-creatinine ratio >50
mg/mmol. Hypomagnesemia was deﬁned as serum
magnesium <0.7 mmol/l and hyperuricemia as a serum urate level
above the upper limit of the normal reference range for age and sex
from the analyzing laboratory. Diabetes was diagnosed either ac-
cording to World Health Organization guidelines or on the basis
of established treatment with oral hypoglycemic agents/insulin.
Abnormal liver function tests were deﬁned as serum alanine
aminotransferase, aspartate transaminase, gamma-glutamyl trans-
ferase, or alkaline phosphatase levels above the upper limit of
the normal reference range for age and sex from the analyzing
laboratory.
Brief behavioral screening was carried out in 4- to 16-year-olds
using the SDQ.42 The questionnaire was completed by parents and
included 25 items on psychological attributes covering 5 areas: (i)
emotional symptoms, (ii) conduct problems, (iii) hyperactivity/
inattention, (iv) peer relationship problems, and (v) prosocial
behavior. Scores from areas 1 to 4 were added together to generate a
total difﬁculties score. An impact supplement was also administered,
which provided further information on chronicity, distress, social
impairment, and burden to others if the child was felt to have a
problem.
Autistic traits were assessed using the AQ in participants of
normal intelligence (deﬁned in this study as IQ $ 70). Three
different versions of this questionnaire were available from the
Autism Research Centre depending on participant age: child
(completed by the parent of each child participant aged 4–11 years),
adolescent (completed by the parent of each child participant aged
12–15 years), and adult (completed by each participant aged $16
years).35–37 AQ scores were converted to percentages for standardi-
zation between the different age groups. Cognitive ability was
assessed in all participants using the Kaufman Brief Intelligence
Test.43 This is an individually administered measure of verbal and
nonverbal intelligence, which yields an overall score known as the
IQ composite (an age-based standard score with a mean  SD of
100  15).
Facial photographs of participants were taken and assessed by 2
experienced clinical geneticists for dysmorphic features previously
associated with the 17q12 deletion. The assessors were blinded to209
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measured and converted to a percentile using British 1990 (UK90)
growth reference charts for children and separate centile charts for
adults.44 Macrocephaly was deﬁned as head circumference >90th
percentile.
Statistical analysis
Qualitative variables were described with percentages and quantitative
variables with median and IQR. Differences between HNF1B gene
mutation and deletion groups were assessed using the Fisher exact test
for categorical variables and the Mann-Whitney U test for continuous
variables. A P-value of <0.05 was considered to be statistically sig-
niﬁcant. The Bonferroni method was used to correct for multiple
comparisons when evaluating dysmorphic features and interrater
agreement between the 2 independent assessors was quantiﬁed using
the Cohen kappa coefﬁcient. All analyses were carried out using
StataSE (version 13.1, StataCorp, College Station, TX) and GraphPad
statistical software (GraphPad Software, La Jolla, CA).
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Investigator award.SUPPLEMENTARY MATERIAL
Figure S1. Patient difﬁculties as shown by subsections of the parent-
reported Strengths and Difﬁculties Questionnaire (SDQ) scores
(presented as Z-scores) for individuals <18 years with both HNF1B
gene mutations (n ¼ 4) and 17q12 microdeletions (n ¼ 10). Individual
scores are represented as different-shaped points and group medians
as black bold horizontal lines. The X-axis represents school-age
population mean, and the red dashed horizontal line above repre-
sents the suggested clinical cut-point (90th percentile).
Table S1. Details of intragenic HNF1B mutations.
Table S2. General characteristics of participants and nonparticipants
who were eligible to take part in the study. F, female; IQR,
interquartile range; M, male. yAll had either an HNF1B point mutation
or whole-gene deletion on previous genetic testing and current
age $4 years. *Other renal structural abnormalities included single
kidney, collecting system abnormalities and bilateral hydronephrosis;
in 5 cases the imaging results were not known.
Table S3. Details of study patients with HNF1B-associated disease
and a clinically diagnosed neurodevelopmental disorder. ADHD,
attention deﬁcit hyperactivity disorder; ASD, autism spectrum disor-
der; AQ, Autism Spectrum Quotient; IQ, intelligence quotient; SDQ,
Strengths and Difﬁculties Questionnaire.
Table S4. Assessment of facial dysmorphic features in study patients
with either HNF1B mutation or 17q12 microdeletion by 2
independent clinical geneticists (Charles Shaw-Smith and Peter
Turnpenny). yThe presence of a clinical feature was determined using
the results of 1 or both assessors; interrater agreement between the 2
assessors was quantiﬁed using the Cohen kappa coefﬁcient. *The
Bonferroni method was used to correct for multiple comparisons;
statistical signiﬁcance was reset at P ¼ 0.004 (0.05/13).
Supplementary material is linked to the online version of the paper
at www.kidney-international.org.210REFERENCES
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